Chemotherapeutic neuropathy

Current Opinion in Neurology

Volumn 12, Issue 5, 1999, Pages 565-571

  Windebank, Anthony J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOSPORIN; DOCETAXEL; DOLOSTATIN 10; DOXORUBICIN; GROWTH FACTOR; IMMUNOPHILIN; OLIGOPEPTIDE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; RAPAMYCIN; SURAMIN; TACROLIMUS; TAXANE DERIVATIVE; TETRAPLATIN; UNCLASSIFIED DRUG; VINCA ALKALOID;

CANCER; CHEMOTHERAPY; HUMAN; NEUROTOXICITY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; NEURONS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 0033397107     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199910000-00010     Document Type: Review

References (77)

1. 1 Reed E, Dabholkar M, Chabner BA. Platinum analogues. In: Cancer chemotherapy and biotherapy: principles and practice, 2nd ed. Chabner BA, Longo DL (editors). Philadelphia: Lippincott-Raven Publishers; 1996. pp. 357-378.
2. 2 Windebank AJ. Drug-induced neuropathies. Baillieres Clin Neurol 1995; 4:529-573.
3. 3 Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Robins HI, Spriggs DR. Phase I trial and pharmacokinetic study of ormaplatin. Proc Am Assoc Cancer Res 1992; 33:536.
4. 4 Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9:1053-1071. This is a comprehensive review of the mechanism of action of oxaliplatin and discussion of the prominent, dose-related, and dose-limiting sensory neuropathy.
5. •] with more emphasis on clinical studies; conclusions are similar to those in the previous reference.
6. 6 McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Safety 1995; 13:228-244.
7. 7 Cavaletti G, Bogliun G, Zincone A, et al. Neuro-and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients. Anticancer Res 1998; 18:3797-3802. This paper provides a demonstration that carboplatin potentially has the same type of neurotoxicity as cisplatin when used in high doses.
8. 8 Cavaletti G, Fabbrica D, Minoia C, Frattola L, Tredici G. Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol 1998; 9:443-447. This is an animal study in which cisplatin and carboplatin were shown to have the same pattern of neurotoxicity when carboplatin is used at high dose levels.
9. 9 Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of Taxol. Monogr Natl Cancer Inst 1993; : 107-115.
10. 10 Hilkens PHE, Verweij J, Stoter G, Vecht CJ, van Putten WLJ, van den Bent MJ. Peripheral neurotoxicity induced by docetaxel. Neurology 1996; 46:104-108.
11. 11 New PZ, Jackson CE, Rinaldi D, Burris H, Barohn RJ. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 1996; 46: 108-111.
12. 12 Pilot HC, McElroy EA Jr, Reid JR, et al. Phase I trial of Dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 1999; 5:525-531. This paper is the first report of successful use of in-vitro testing for predicting neurotoxicity in patients.
13. 13 LaRocca RV, Meer J, Gilliatt RW, et al. Suramin-induced polyneuropathy. Neurology 1990; 40:954-960.
14. 14 Chaudhry V, Eisenberger MA, Sinibaldi VJ, Sheikh K, Griffin JW, Cornblath DR. A prospective study of suramin-induced peripheral neuropathy. Brain 1996; 119:2039-2052.
15. 15 Soliven B, Dhand UK, Kobayashi K, et al. Evaluation of neuropathy in patients on suramin treatment. Muscle Nerve 1997; 20:83-91.
16. 16 Cavaletti G, Bogliun G, Crespi V, et al. Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer. J Clin Oncol 1997; 15:199-206.
17. 17 Hilkens PHE, Pronk LC, Verweij J, Vecht CJ, van Putten WLJ, van den Bent MJ. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer 1997; 75:417-422.
18. 18 Huang H, Zhu L, Reid BR, Drobny GP, Hopkins PB. Solution structure of a cisplatin-induced DNA interstrand cross-link. Science 1995; 270:1842-1845.
19. 19 Ohndorf U-M, Rould MA, He Q, Pabo CO, Lippard SJ. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature 1999; 399:708-712.
20. 20 Li QD, Gardner K, Zhang LJ, Tsang B, Bostickbruton F, Reed E. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 1998; 273:23419-23425.
21. L. J Biol Chem 1996; 271:22764-22772.
22. 22 McCurrach ME, Connor TMF, Knudson CM, Korsmeyer SJ, Lowe SW. baxdeficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci USA 1997; 94:2345-2349.
23. 23 Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80:293-299.
24. 24 Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57:3823-3829.
25. 25 Müller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99:403-413.
26. 26 Eischen CM, Kottke TJ, Martins LM, et al. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 1997; 90:935-943.
27. 27 Aloyz RS, Bamji SX, Pozniak CD, et al. p53 is essential for developmental neuron death as regulated by the TrkA and p75 neurotrophin receptors. J Cell Biol 1998; 143:1691-1703.
28. 28 Vogel KS, Parada LF. Sympathetic neuron survival and proliferation are prolonged by loss of p53 and neurofibromin. Mol Cell Neurosci 1998; 11:19-28.
29. 29 Xiang H, Kinoshita Y, Knudson CM, Korsmeyer SJ, Schwartzkroin PA, Morrison RS. Bax involvement in p53-mediated neuronal cell death. J Neurosci 1998; 18:1363-1373. This paper links p53 regulation of Bax expression in neuronal death. It uses glutamate-induced excitotoxic death of cortical and cerebellar neurons in culture as a model system.
30. 30 Enokido Y, Araki T, Tanaka K, Aizawa S, Hatanaka H. Involvement of p53 in DNA strand break-induced apoptosis in postmitotic CNS neurons. Eur J Neurosci 1996; 8:1812-1821.
31. 31 Wood KA, Youle RJ. The role of free radicals and p53 in neuron apoptosis in vivo. J Neurosci 1995; 15:5851-5857.
32. 32 Gill JS, Windebank AJ. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 1998; 101:2842-2850. This study demonstrates potential mechanisms for cisplatin neurotoxicity and for rescue by NGF which has been shown by several groups in different model systems. See also [38,39].
33. 33 Cavaletti G, Tredici G, Marmiroli P, Petruccioli MG, Barajon I, Fabbrica D. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol (Berl) 1992; 84:364-371.
34. 34 Cece R, Petruccioli MG, Cavaletti G, Barajon I, Tredici G. An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations. Histol Histopathol 1995; 10:837-845.
35. 35 Tomiwa K, Nolan C, Cavanagh JB. The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry. Acta Neuropathol (Berl) 1986; 69:295-308.
36. 36 Gregg RW, Molepo JM, Monpetit VJA, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992; 10:795-803.
37. 37 Vandertop WP, de Vries WB, Notermans NC, et al. Cisplatin-induced autonomic neuropathy: does it really exist? J Neurooncol 1996; 27:53-60.
38. 38 Park DS, Levine B, Ferrari G, Greene LA. Cyclin dependent kinase inhibitors and dominant negative cyclin dependent kinase 4 and 6 promote survival of NGF-deprived sympathetic neurons. J Neurosci 1997; 17:8975-8983.
39. 39 Park DS, Morris EJ, Greene LA, Geller HM. G1/S cell cycle blockers and inhibitors of cyclin-dependent kinases suppress camptothecin-induced neuronal apoptosis. J Neurosci 1997; 17:1256-1270.
40. 40 Park DS, Morris EJ, Stefanis L, et al. Multiple pathways of neuronal death induced by DNA-damaging agents, NGF deprivation, and oxidative stress. J Neurosci 1998; 18:830-840.
41. 41 Rowinsky EK, Donehower RC. Antimicrotubule agents. In: Cancer chemotherapy and biotherapy, 2nd ed. Chabner BA, Longo DL (editors). Philadelphia: Lippincott-Raven Publishers; 1996. pp. 263-296.
42. 42 Röyttä M, Horwitz SB, Raine CS. Taxol-induced neuropathy: short-term effects of local injection. J Neurocytol 1984; 13:685-701.
43. 43 Cavaletti G, Cavalletti E, Montaguti P, Oggioni N, De Negri O, Tredici G. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 1997; 18:137-145.
44. 44 Gill JS, Windebank AJ. Suramin induced ceramide accumulation leads to apoptotic cell death in dorsal root ganglion neurons. Cell Death Diff 1998; 5:876-883.
45. 45 Gill JS, Connolly DC, McManus MJ, Maihle NJ, Windebank AJ. Suramin induces phosphorylation of the high-affinity nerve growth factor receptor in PC 12 cells and dorsal root ganglion neurons. J Neurochem 1996; 66:963-972.
46. 46 Gill JS, Windebank AJ. Direct activation of the high-affinity nerve growth factor receptor by a non-peptide symmetrical polyanion. Neuroscience 1998; 87:855-860.
47. 47 Russell JW, Windebank AJ, Podratz JL. Role of nerve growth factor in suramin neurotoxicity studied in vitro. Ann Neurol 1994; 36:221-228.
48. 48 Constantopoulos G, Rees S, Cragg BG, Barranger JA, Brady RO. Experimental animal model for mucopolysaccharidosis: suramin-induced glycosaminoglycan and sphingolipid accumulation in the rat. Proc Natl Acad Sci USA 1980; 77:3700-3704.
49. 49 Constantopoulos G, Rees S, Cragg BG, Barranger JA, Brady RO. Suramin-induced storage disease. Mucopolysaccharidosis. Am J Pathol 1983; 113:266-268.
50. 50 Gill JS, Hobday KL, Windebank AJ. Mechanism of suramin toxicity in stable myelinating dorsal root ganglion cultures. Exp Neurol 1995; 133:113-124.
51. 51 Wiesner DA, Dawson G. Programmed cell death in neurotumour cells involves the generation of ceramide. Glycoconjugate J 1996; 13:327-333.
52. 52 Gill JS, Windebank AJ. Role of ceramide in suramin-induced cancer cell death. Cancer Lett 1997; 119:169-176.
53. 53 Hannun YA, Obeid LM. Ceramide: an intracellular signal for apoptosis. Trends Biochem Sci 1995; 20:73-77.
54. 54 Dawson G, Goswami R, Kilkus J, Wiesner D, Dawson S. The formation of ceramide from sphingomyelin is associated with cellular apoptosis. Acta Biochimica Polonica 1998; 45:287-297.
55. 55 Wiesner DA, Dawson G. Staurosporine induces programmed cell death in embryonic neurons and activation of the ceramide pathway. J Neurochem 1996; 66:1418-1425.
56. 56 Gill JS, Windebank AJ. NFΚB activation in chemotherapy induced peripheral neuropathy. J Neurochem 1998; 70:S5D.
57. 57 Beguin Y. A risk-benefit assessment of epoetin in the management of anaemia associated with cancer. Drug Safety 1998; 19:269-282.
58. 58 Kumar M, Alter BP. Hematopoietic growth factors for the treatment of aplastic anemia. Curr Opin Hematol 1998; 5:226-234.
59. 59 Clemons M, Gharif R, Howell A. The value of dose intensification of standard chemotherapy for advanced breast cancer using colony-stimulating factors alone. Cancer Treat Rev 1998; 24:173-184.
60. 60 Apfel SC, Lipton RB, Arezzo JC, Kessler JA. Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 1991; 29:87-90.
61. 61 Apfel SC, Arezzo JC, Lipson L, Kessler JA. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 1992; 31:76-80.
62. 62 Hayakawa K, Sobue G, Itoh T, Mitsuma T. Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol, on adult rat sympathetic ganglion expiants in vitro. Life Sci 1994; 55:519-525.
63. 63 Gao W-Q, Dybdal N, Shinsky N, et al. Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Neurol 1995; 38:30-37.
64. 64 Zheng JL, Stewart RR, Gao WQ. Neurotrophin-4/5 enhances survival of cultured spiral ganglion neurons and protects them from cisplatin neurotoxicity. J Neurosci 1995; 15:5079-5087.
65. 65 Hayakawa K, Itoh T, Niwa H, Mutoh T, Sobue G. NGF prevention of neurotoxicity induced by cisplatin, vincristine and taxol depends on toxicity of each drug and NGF treatment schedule: in vitro study of adult rat sympathetic ganglion expiants. Brain Res 1998; 794:313-319.
66. 66 Hamers FPT, Pette C, Neijt JP, Gispen W-H. The ACTH-(4-9) analog, ORG 2766, prevents taxol-induced neuropathy in rats. Eur J Pharmacol 1993; 233:177-178.
67. 67 Gerritsen van der Hoop R, Hamers FPT, Neijt JP, Veldman H, Gispen WH, Jennekens FGI. Protection against cisplatin induced neurotoxicity by ORG 2766: histological and electrophysiological evidence. J Neurol Sci 1994; 126:109-115.
68. 68 Windebank AJ, Smith AG, Russell JW. The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology 1994; 44:488-494.
69. 69 Roberts JA, Jenison EL, Kim K, Clarke-Pearson D, Langleben A. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 1997; 67:172-177.
70. 70 Campana WM, Eskeland N, Calcutt NA, Misasi R, Myers RR, O'Brien JS. Prosaptide prevents paclitaxel neurotoxicity. Neurotoxicology 1998; 19:237-244.
71. 71 Sumiyoshi Y, Hashine K, Kasahara K, Karashima T. Glutathione chemoprotection therapy against CDDP-induced neurotoxicity in patients with invasive bladder cancer [in Japanese]. Jpn J Cancer Chemother 1996; 23:1506-1508.
72. 72 Smyth JF, Bowman A, Perren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol 1997; 8:569-573.
73. 73 Tredici G, Tredici S, Fabbrica D, Minoia C, Cavaletti G. Experimental cisplatin neuronopathy in rats and the effect of retinoic acid administration. J Neurooncol 1998; 36:31-40.
74. 74 Steiner JP, Connolly MA, Valentine HL, et al. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nature Med 1997; 3:421-428.
75. 75 Steiner JP, Hamilton GS, Ross DT, et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Natl Acad Sci USA 1997; 94:2019-2024.
76. 76 Kikuchi M, Kashii S, Mandai M, et al. Protective effects of FK506 against glutamate-induced neurotoxicity in retinal cell culture. Invest Ophthalmol Vis Sci 1998; 39:1227-1232.
77. 77 Moriwaki A, Lu Y-F, Tomizawa K, Matsui H. An immunosuppressant, FK506, protects against neuronal dysfunction and death but has no effect on electrographic and behavioral activities induced by systemic kainate. Neuroscience 1998; 86:855-865.